IGF-1R inhibition potentiates cytotoxic effects of chemotherapeutic agents in early stages of chemoresistant ovarian cancer cells

• Published in: Cancer letters Vol. 354; no. 2; pp. 254 - 262
• Main Authors: Singh, Ram K, Gaikwad, Snehal M, Jinager, Ankit, Chaudhury, Smrita, Maheshwari, Amita, Ray, Pritha
• Format: Journal Article
• Language: English
• Published: Ireland Elsevier Ireland Ltd 28.11.2014; Elsevier Limited
• Subjects: Adapter proteins; Antineoplastic Combined Chemotherapy Protocols - pharmacology; Cancer therapies; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Chemoresistance; Chemotherapy; Cisplatin - administration & dosage; Cisplatin - pharmacology; Clinical trials; Cytotoxicity; Down-Regulation; Drug dosages; Drug Resistance, Neoplasm; Drug Synergism; Female; Hematology, Oncology and Palliative Medicine; Humans; IGF-1R signaling; Kinases; Ligands; Molecular Targeted Therapy; Neoplasm Staging; Neoplasms, Glandular and Epithelial - drug therapy; Neoplasms, Glandular and Epithelial - metabolism; Neoplasms, Glandular and Epithelial - pathology; Ovarian cancer; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - metabolism; Ovarian Neoplasms - pathology; Paclitaxel - administration & dosage; Paclitaxel - pharmacology; Podophyllotoxin - administration & dosage; Podophyllotoxin - analogs & derivatives; Podophyllotoxin - pharmacology; Proteasome Endopeptidase Complex - metabolism; Receptor, IGF Type 1 - antagonists & inhibitors; Receptor, IGF Type 1 - biosynthesis; Tumors; IGF-1R signaling; Chemoresistance; Ovarian cancer

Highlights • IGF-1R expression elevates at early stages of chemoresistance in EOC cells. • PPP, an IGF-1R inhibitor exhibits maximal resistance reversal at early stages. • PPP with cisplatin, paclitaxel and both at low doses exert significant efficacy. • IGF-1R expression increases in ovarian cancer...